Literature DB >> 12450688

Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates.

Koert J Stittelaar1, Helma W Vos, Geert van Amerongen, Gideon F A Kersten, Albert D M E Osterhaus, Rik L de Swart.   

Abstract

Quil A-based candidate measles vaccines have been shown to be immunogenic and protective in cotton rats and macaques. Here we studied the longevity of protective VN antibody levels induced in macaques with one dose of measles virus (MV) iscom. Inactivated MV adjuvanted with iscom-matrix or with purified Quillaja saponin QA-22 were also tested. All animals developed high levels of VN antibody and MV-specific IFNgamma-producing cells. Especially the high VN antibody levels induced by the latter two preparations showed virtually no decrease during the 2-year follow-up. These highly promising candidate MV vaccines should now be tested in infant macaques in the presence or absence of passively transferred and/or maternally derived VN antibodies. In addition, the immunopathological safety of the constructs should be evaluated in the atypical measles model in rhesus macaques.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450688     DOI: 10.1016/s0264-410x(02)00453-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Chikungunya virus arthritis in adult wild-type mice.

Authors:  Joy Gardner; Itaru Anraku; Thuy T Le; Thibaut Larcher; Lee Major; Pierre Roques; Wayne A Schroder; Stephen Higgs; Andreas Suhrbier
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

2.  Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.

Authors:  Chien-Hsiung Pan; Alexandra Valsamakis; Teresa Colella; Nitya Nair; Robert J Adams; Fernando P Polack; Catherine E Greer; Silvia Perri; John M Polo; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

3.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

4.  Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.

Authors:  Chien-Hsiung Pan; Gretchen S Jimenez; Nitya Nair; Qun Wei; Robert J Adams; Fernando P Polack; Alain Rolland; Adrián Vilalta; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

5.  Immunization of rhesus macaques with Echinococcus multilocularis recombinant 14-3-3 antigen leads to specific antibody response.

Authors:  Karen Lampe; B Gottstein; T Becker; C Stahl-Hennig; F-J Kaup; K Mätz-Rensing
Journal:  Parasitol Res       Date:  2016-10-27       Impact factor: 2.289

Review 6.  Measles studies in the macaque model.

Authors:  R L de Swart; R L DeSwart
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.